Skip to main content

Advertisement

Table 1 Cohort demographics

From: Endo-lysosomal proteins and ubiquitin CSF concentrations in Alzheimer’s and Parkinson’s disease

Cohort Group N (F/M) Age, median (IQR) N, APOE ε4 +/−a 1–42 ng/L, median (IQR) P-tau181 ng/L, median (IQR) T-tau ng/L, median (IQR)
Pilot study Control 24 (8/16) 72 (62–74) 833 (714–998) 42 (36–51) 288 (218–320)
AD 19 (9/10) 76 (71–81)b 390 (351–456)c 92 (81–104)c 940 (710–1090)c
Clinical study I Stable MCI 15 (6/9) 67 (59–76) 1200 (880–1500) 54 (40–59) 230 (190–320)
Prodromal AD 10 (7/3) 66 (59–74) 380 (270–480)d,e 96 (77–160)f,g 690 (510–1100)f,g
AD 6 (2/4) 70 (57–79) 400 (330–460)d 98 (81–120)g,h 600 (540–860)g,h
PD 10 (5/5) 60 (54–68) 850 (580–1000) 34 (24–48) 140 (110–180)
Clinical study II Control 44 (30/14) 75 (68–78) 10/17 890 (660–1100) 45 (38–53) 320 (270–390)
AD 36 (23/13) 73 (67–77) 25/10 380 (300–440)i,j 74 (65–100)g,i 680 (510–870)g,i
PD 11 (6/5) 69 (68–76) 660 (430–910) 37 (33–47) 220 (170–320)
  1. aN carriers of one or two APOE ε4 alleles (+) and non-carriers (−)
  2. bP ≤ 0.01, vs control, Wilcoxon 2-sample rank sum test
  3. cP ≤ 0.0001, vs control, Wilcoxon 2-sample rank sum test
  4. dP ≤ 0.001, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
  5. eP ≤ 0.05, vs PD, Kruskal-Wallis test with Dunn post hoc
  6. fP ≤ 0.01, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
  7. gP ≤ 0.001, vs PD, Kruskal-Wallis test with Dunn post hoc
  8. hP ≤ 0.05, vs stable MCI, Kruskal-Wallis test with Dunn post hoc
  9. iP ≤ 0.001, vs control, Kruskal-Wallis test with Dunn post hoc
  10. jP ≤ 0.01, vs PD, Kruskal-Wallis test with Dunn post hoc